GlassScriptPhysician profile
Bryan A Hynes
NPI 1881839694
$2,717.00
in general payments reported to CMS, 2019-2025
31 companies · $868 in 2025
The $868 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.43 · 2020: $154 · 2021: $82.43 · 2022: $450 · 2023: $625 · 2024: $503 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,996.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $403.78 | 2021-2025 | |
| Novo Nordisk INC | $329.81 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $207.80 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.42 | 2022-2025 | Xifaxan |
| Horizon Therapeutics Plc | $172.37 | 2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $158.29 | 2023-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $126.86 | 2023-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $117.21 | 2022-2025 | |
| Glaxosmithkline, LLC. | $100.17 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $93.00 | 2022 | |
| Astellas Pharma US INC | $90.32 | 2022-2025 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $88.49 | 2020 | |
| Inspire Medical Systems, INC. | $70.21 | 2024 | Inspire |
| Viiv Healthcare Company | $65.01 | 2024-2025 | Apretude |
| Amgen INC. | $59.34 | 2024-2025 | Krystexxa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.96 | 2024-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $47.16 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $44.09 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $36.53 | 2024-2025 | Zenpep |
| Sumitomo Pharma America, INC. | $33.08 | 2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.68 | 2019-2022 | |
| Insulet Corporation | $29.03 | 2025 | Omnipod |
| Almatica Pharma LLC | $26.66 | 2025 | Loreev Xr |
| Axsome Therapeutics, INC. | $21.14 | 2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $19.70 | 2022 | |
| Pfizer INC. | $19.56 | 2023 | |
| Tonix Medicines, INC. | $18.94 | 2025 | Tonmya |
| Dexcom, INC. | $18.83 | 2023 | Dexcom G6 Transmitter |
| Vertex Pharmaceuticals Incorporated | $16.52 | 2025 | |
| Exact Sciences Corporation | $15.78 | 2023 | Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Hynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.